Inhibiting mutant idh-1
AssigneeFORMA Therapeutics, Inc.
InventorsPatrick F. Kelly, Alan Collis, Jeff Davis, Duncan Walker, Susan Ashwell, Blythe Thomson, Wei Lu
Life of this patent
Estimating the term…
Abstract
Methods of treating patients diagnosed with cancer harboring an IDH-1 mutation are provided, including the therapeutic administration of a certain inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA).
Claims13
1-15. (canceled)
A method of treating an adult patient with acute myeloid leukemia having a susceptible IDH1 mutation as detected by an FDA-approved test, comprising administering to the patient having acute myeloid leukemia having a susceptible IDH1 mutation as detected by an FDA-approved test, 150 mg of olutasidenib once daily.
A method of treating a transfusion-dependent adult patient with acute myeloid leukemia having a susceptible IDH1 mutation as detected by an FDA-approved test, comprising administering to the patient having a transfusion-dependent adult patient with acute myeloid leukemia having a susceptible IDH1 mutation as detected by an FDA-approved test, 150 mg of olutasidenib once daily.
Dependencies are inferred from the claim text.